In a 6-month prospective study of all admissions ( N = 72) to an old age psychiatric unit, 34% ( N = 24) were found to have significant physical illnesses at the time of admission. Sixty-two per cent of the conditions were detected by a combination of clinical methods and simple tests alone. There w
Depression in elderly physically ill inpatients: A 12-month prospective study
✍ Scribed by Dr. Mavis E. Evans
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 521 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0885-6230
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
A 12‐month prospective study of a randomly selected group of acute geriatric medical inpatients was carried out. Twenty‐three of the original sample of 72 were diagnosed as cases of depression on entry into the study and commenced on treatment with fluoxetine 20 mg mane. Follow‐up at 3 months showed a significantly increased death rate in the depressed group (p < 0.05) which was reversed in those surviving to 12 months, this trend to a lower mortality not reaching significance. Two patients did not continue their antidepressants after leaving hospital and remained depressed at 3‐month follow‐up. The effect of treatment versus no treatment was significant (p < 0.03). The incidence of depression in the psychologically well group was 14% over the 12‐month period, understandably high when seen in the context of their continuing physical problems. None of the treated depressed group relapsed during the study period.
📜 SIMILAR VOLUMES
A pilot study compared the difficulties faced by co-resident relatives caring for elderly patients with dementia and those with depression, referred to a psychogeriatric service in London. The mean GHQ-28 score of 23 dementia carers was significantly higher than that of 17 carers of elderly people w
## Objective To compare the effectiveness of amisulpride in acute (up to 8 weeks) and maintenance (week 8 to 12 months) phases of a 12‐month course of treatment in a heterogeneous group of patients with schizophrenia. ## Methods We conducted a 12‐month, open‐label clinical trial with flexible dos